Description
CI-1044 is a potent, selective and orally bioavailable PDE4 inhibitor with IC50 of 0.27uM, displays high selectivity for PDE4 versus PDE1/3/5, and no PDE4 subtype (4A-D) selectivities; exhibits efficient in vitro inhibition of TNFalpha release from hPBMC and hWB with IC50 of 0.34 and 0.84uM, respectively; exhibits potent in vivo activity in antigen-induced eosinophil recruitment in rats (ED50=3.2mg/kg, p. O.). Asthma Phase 1 Clinical